Interní Med. 2010; 12(6): 306-307

Current position of betablockers in treatment of arterial hypertension

MUDr.Eduard Němeček, prof.MUDr.Aleš Linhart, DrSc.
2. interní klinika kardiologie a angiologie 1. LF UK a VFN, Praha

In cardiology betablockers have a big importance in secondary preventative indications. Their very important task is evidenced in treatment of

patients who suffer from ischemic heart disease and also in treatment of heart failure of patients who suffer from systolic dysfunction. Although

in most of recommendation they are presented like medicine of the first choice in arterial hypertension, evidence for their administration in

this indication is not by far so strong. We can explain it by their negative impact on metabolism (overweight, negative affection of lipid profile,

setback resistence to insulin, more frequent recurrence of diabetes) and heamodynamic insufficient influence of central blood pressure.

Keywords: betablockers, arterial hypertension

Published: July 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Němeček E, Linhart A. Current position of betablockers in treatment of arterial hypertension. Interní Med. 2010;12(6):306-307.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Liao D, Cai J, Barnes RW, et al. Association of cardiac autonomic function and the development of hypertension: the ARIC study. Am J Hypertens 1996; 9: 1147-1156. Go to original source... Go to PubMed...
    2. Widimský J jr., Cífková R, Špinar J, et al. Doporučení diagnostických a léčebných postupů u arteriální hypertenze - verze 2007. Cor Vasa 2008; 50(1): Kardio: K3-K16.
    3. Wikstrand J, Warnold I, Tuomilehto J, et al. Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY study. Hypertension 1991; 17: 579-588. Go to original source... Go to PubMed...
    4. Hansson L, Lindholm LH, Niskanen L, et al. for the Captopril Prevention Project (CAPP) study group. Effect of angiotensin-converting-enzym inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial. Lancet 1999; 353: 611. Go to original source... Go to PubMed...
    5. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian CardiacOutcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906. Go to original source... Go to PubMed...
    6. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For End Point Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003. Go to original source... Go to PubMed...
    7. Dahlöf B, Pennert K, Hansson L. Regression of left ventricular hypertrophy-a meta-analysis. Clin Exp Hypertens 1992; 14(1-2): 173-180. Go to original source... Go to PubMed...
    8. Schmieder RE, Schlaich MP. Comparison of therapeutic studies on regression of left ventricular hypertrophy. Adv Exp Med Biol. 1997; 432: 191-198. Go to original source... Go to PubMed...
    9. Sever PS, Dahlof B, Poulter NR, et al. ASCOT investigators: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003; 361: 1149-1158. Go to original source... Go to PubMed...
    10. Wright JM. Choosing a first-line drug in the management of elevated blood pressure: what is the evidence? 2: Betablockers. CMAJ 2000; 25, 163(2): 188-192. Go to PubMed...
    11. Lindholm LH, Carlberg B, Samuelsson O. Should blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545-1553. Go to original source... Go to PubMed...
    12. Bangalore S, Sawhney S, Messerli FH. Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol. 2008; 28; 52(18): 1482-1489. Go to original source... Go to PubMed...
    13. Kernis SJ, Harjai KJ, Stone GW, et al. Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? J Am Coll Cardiol. 2004; 19, 43(10): 1773-1779. Go to original source... Go to PubMed...
    14. Bangalore S, Parkar S, Grossman E, et al. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol. 2007; 100: 1254-1262. Go to original source... Go to PubMed...
    15. Williams B, Lacy PS, Thom SM, et al. CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213-1225. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.